European Society for Medical Oncology Immuno-Oncology Congress 2022

20 $

+ Include: 122 videos + 314 pdf, size: 15.5 GB

+ Target Audience: oncologist, immunologist

Description

+ Include: 122 videos + 314 pdf, size: 15.5 GB

+ Target Audience: oncologist, immunologist

+ Sample video: contact me for sample video

+ Information:

The ESMO Immuno-Oncology Congress took placeĀ as an onsite event in Geneva, Switzerland, 7-9 December 2022, as well as online, through a dedicated virtual platform.

The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.

From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress caters to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

 

 

+ Topics:

B cells as a therapeutic opportunity Antibody responses in the TME.mp4
B cells as a therapeutic opportunity Antibody responses in the TME.pdf
B cells as a therapeutic opportunity B cell function within tertiary lymphoid structures.mp4
B cells as a therapeutic opportunity B cell function within tertiary lymphoid structures.pdf
B cells as a therapeutic opportunity Q&A.mp4
B cells as a therapeutic opportunity Tertiary lymphoid structure formation in non-small cell lung cancer.mp4
B cells as a therapeutic opportunity Tertiary lymphoid structure formation in non-small cell lung cancer.pdf
Bristol Myers Squibb – Exploring new advancements in chemokine signaling Caught in a NET Reviewing IL-8, CXCR1, and CXCR2 signaling in tumor biology.mp4
Bristol Myers Squibb – Exploring new advancements in chemokine signaling Closing remarks and audience Q&A.mp4
Bristol Myers Squibb – Exploring new advancements in chemokine signaling Emerging data for targeting IL-8, CXCR1, and or CXCR2.mp4
Bristol Myers Squibb – Exploring new advancements in chemokine signaling Spotlight on I-O Chemokine signaling and its role in tumor development and I-O resistance.mp4
Bristol Myers Squibb – Exploring new advancements in chemokine signaling Welcome and introductions.mp4
Cancer vaccines Promise or dead end Introduction and first vote.mp4
Cancer vaccines Promise or dead end Promise.mp4
Cancer vaccines Promise or dead end Promise.pdf
Cancer vaccines Promise or dead end Second vote and conclusions.mp4
Combination of radiotherapy and immunotherapy is a good idea Introduction and first vote.mp4
Combination of radiotherapy and immunotherapy is a good idea Introduction and first vote.pdf
Combination of radiotherapy and immunotherapy is a good idea No.mp4
Combination of radiotherapy and immunotherapy is a good idea No.pdf
Combination of radiotherapy and immunotherapy is a good idea Second vote and conclusions.mp4
Combination of radiotherapy and immunotherapy is a good idea Second vote and conclusions.pdf
Epigenetic immunomodelling Epigenetic remodelling in melanoma.mp4
Epigenetic immunomodelling Epigenetic remodelling in melanoma.pdf
Epigenetic immunomodelling Q&A.mp4
Epigenetic immunomodelling T cell differentiation.mp4
Epigenetic immunomodelling T cell differentiation.pdf
final_programme_immuno22hybrid.pdf
GI tumours Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers.mp4
GI tumours Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers.pdf
GI tumours New IO combinations and biomarkers in oesophageal and gastric cancers.mp4
GI tumours New IO combinations and biomarkers in oesophageal and gastric cancers.pdf
GI tumours Q&A.mp4
GI tumours Response and resistance in MMR deficient colorectal cancer Insights from mouse and man.mp4
GI tumours Response and resistance in MMR deficient colorectal cancer Insights from mouse and man.pdf
GI tumours Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer.mp4
GI tumours Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer.pdf
GSK The need to advance checkpoint blockade for cancer immunotherapy How does the CD226 Axis regulate antitumor responses.mp4
GSK The need to advance checkpoint blockade for cancer immunotherapy How is the CD226 Axis being studied in clinical trials.mp4
GSK The need to advance checkpoint blockade for cancer immunotherapy Panel discussion Q&A.mp4
GSK The need to advance checkpoint blockade for cancer immunotherapy What is the CD226 Axis.mp4
GSK The need to advance checkpoint blockade for cancer immunotherapy Why is there a need to build on current immune checkpoint therapies.mp4
GU malignancies Bladder cancer immunotherapy.mp4
GU malignancies Bladder cancer immunotherapy.pdf
GU malignancies IO in renal cell carcinoma The latest on combining and sequencing.mp4
GU malignancies IO in renal cell carcinoma The latest on combining and sequencing.pdf
GU malignancies Prostate cancer immunotherapy.mp4
GU malignancies Prostate cancer immunotherapy.pdf
GU malignancies Q&A.mp4
Gynaecological malignancies and breast tumours Breast cancer immunotherapy overview.mp4
Gynaecological malignancies and breast tumours Breast cancer immunotherapy overview.pdf
Gynaecological malignancies and breast tumours Immunotherapy plus PARP.mp4
Gynaecological malignancies and breast tumours Immunotherapy plus PARP.pdf
Gynaecological malignancies and breast tumours Q&A.mp4
H&N cancers Lessons from neoadjuvant use of immunotherapy before curative-intent surgery.mp4
H&N cancers Lessons from neoadjuvant use of immunotherapy before curative-intent surgery.pdf
H&N cancers Lessons from novel intra-tumoural therapies in head and neck cancer.mp4
H&N cancers Lessons from novel intra-tumoural therapies in head and neck cancer.pdf
H&N cancers Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy.mp4
H&N cancers Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy.pdf
H&N cancers Lessons from trials of systemic immunotherapies in relapsed and or metastatic disease.mp4
H&N cancers Lessons from trials of systemic immunotherapies in relapsed and or metastatic disease.pdf
H&N cancers Q&A.mp4
Haematological malignancies ICI and lymphomas.mp4
Haematological malignancies ICI and lymphomas.pdf
Haematological malignancies Improving outcomes of cellular therapy in non-Hodgkin’s B-cell lymphoma.mp4
Haematological malignancies Improving outcomes of cellular therapy in non-Hodgkin’s B-cell lymphoma.pdf
Haematological malignancies Oncolytic virus therapy A novel immunotherapeutic approach in haematologic malignancies.mp4
Haematological malignancies Oncolytic virus therapy A novel immunotherapeutic approach in haematologic malignancies.pdf
Haematological malignancies Q&A.mp4
Imaging biomarkers in IO for cancer AI and radiomics Results in immunotherapy.mp4
Imaging biomarkers in IO for cancer AI and radiomics Results in immunotherapy.pdf
Imaging biomarkers in IO for cancer MRI techniques to visualise what is happening during immunotherapy.mp4
Imaging biomarkers in IO for cancer MRI techniques to visualise what is happening during immunotherapy.pdf
Imaging biomarkers in IO for cancer Q&A.mp4
Imaging biomarkers in IO for cancer Whole body imaging macrophages.mp4
Imaging biomarkers in IO for cancer Whole body imaging macrophages.pdf
Innate immune effectors Crosstalk between eosinophils and adaptive immune cells dictates response to immune checkpoint blockade in breast cancer.pdf
Innate immune effectors Diversity, function and clinical significance of tumor-associated macrophages.pdf
Innate immune effectors Q&A.mp4
Joint ESMO-SITC Immunotherapy Primer Conclusions.mp4
Joint ESMO-SITC Immunotherapy Primer Panel session.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 1.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 2.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 3.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 4.mp4
Joint ESMO-SITC Immunotherapy Primer Stromal cells in the TME.mp4
Joint ESMO-SITC Immunotherapy Primer Stromal cells in the TME.pdf
Joint ESMO-SITC Immunotherapy Primer The importance of myeloid cells in the TME.mp4
Joint ESMO-SITC Immunotherapy Primer The importance of myeloid cells in the TME.pdf
Joint ESMO-SITC Immunotherapy Primer The microbiome influence on the TME.mp4
Joint ESMO-SITC Immunotherapy Primer The microbiome influence on the TME.pdf
Joint ESMO-SITC Immunotherapy Primer The utility of radiographic imaging and radiotherapy in immunotherapy.mp4
Joint ESMO-SITC Immunotherapy Primer The utility of radiographic imaging and radiotherapy in immunotherapy.pdf
Joint ESMO-SITC Immunotherapy Primer Utilizing oncolytic virus as a new treatment modality.mp4
Joint ESMO-SITC Immunotherapy Primer Utilizing oncolytic virus as a new treatment modality.pdf
Joint ESMO-SITC Immunotherapy Primer Welcome and introduction.mp4
Local therapy for systemic beneficial goals Focal tumour radiotherapy as a trigger for systemic immune response.mp4
Local therapy for systemic beneficial goals Focal tumour radiotherapy as a trigger for systemic immune response.pdf
Local therapy for systemic beneficial goals Intratumoral tumor-specific treg depletion.mp4
Local therapy for systemic beneficial goals Intratumoral tumor-specific treg depletion.pdf
Local therapy for systemic beneficial goals Intratumoural oncolytic virotherapy.mp4
Local therapy for systemic beneficial goals Intratumoural oncolytic virotherapy.pdf
Local therapy for systemic beneficial goals Intratumoural STING agonists.mp4
Local therapy for systemic beneficial goals Intratumoural STING agonists.pdf
Local therapy for systemic beneficial goals Q&A.mp4
Mini Oral session 1 35MO – Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte.mp4
Mini Oral session 1 35MO – Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte.pdf
Mini Oral session 1 36MO – Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes.mp4
Mini Oral session 1 36MO – Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes.pdf
Mini Oral session 1 60MO – Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens.mp4
Mini Oral session 1 60MO – Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens.pdf
Mini Oral session 1 61MO – IMscin001 (Part 2 Randomized Phase III) Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC).mp4
Mini Oral session 1 61MO – IMscin001 (Part 2 Randomized Phase III) Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC).pdf
Mini Oral session 1 Invited Discussant 1.mp4
Mini Oral session 1 Invited Discussant 1.pdf
Mini Oral session 1 Invited Discussant 2.mp4
Mini Oral session 1 Invited Discussant 2.pdf
Mini Oral session 1 LBA2 – Phase II study of PD-L1 Expression Guidance on Neoadjuvant.mp4
Mini Oral session 1 LBA2 – Phase II study of PD-L1 Expression Guidance on Neoadjuvant.pdf
Mini Oral session 1 LBA6 – UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells.pdf
Mini Oral session 2 200MO – Anti-IL-8 BMS-986253 nivolumab (NIVO) ipilimumab (IPI) in patients (pts).mp4
Mini Oral session 2 200MO – Anti-IL-8 BMS-986253 nivolumab (NIVO) ipilimumab (IPI) in patients (pts).pdf
Mini Oral session 2 2MO – First-line (1L) nivolumab (NIVO) + ipilimumab (IPI).mp4
Mini Oral session 2 2MO – First-line (1L) nivolumab (NIVO) + ipilimumab (IPI).pdf
Mini Oral session 2 3MO – Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1 L1 immune checkpoint.mp4
Mini Oral session 2 3MO – Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1 L1 immune checkpoint.pdf
Mini Oral session 2 62MO – Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS.mp4
Mini Oral session 2 62MO – Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS.pdf
Mini Oral session 2 Invited Discussant 1.mp4
Mini Oral session 2 Invited Discussant 1.pdf
Mini Oral session 2 Invited Discussant 2.mp4
Mini Oral session 2 Invited Discussant 2.pdf
Mini Oral session 2 Invited Discussant 3.mp4
Mini Oral session 2 Invited Discussant 3.pdf
Mini Oral session 2 LBA1 – Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression.mp4
Mini Oral session 2 LBA1 – Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression.pdf
Mini Oral session 2 LBA3 – Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma.mp4
Mini Oral session 2 LBA3 – Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma.pdf
Next generation technologies for the optimal implementation of immunotherapy Engineering myeloid CAR-M.mp4
Next generation technologies for the optimal implementation of immunotherapy Engineering myeloid CAR-M.pdf
Next generation technologies for the optimal implementation of immunotherapy Molecular tissue imaging New technologies.mp4
Next generation technologies for the optimal implementation of immunotherapy Molecular tissue imaging New technologies.pdf
Next generation technologies for the optimal implementation of immunotherapy Multi-specific antibody-like platforms.mp4
Next generation technologies for the optimal implementation of immunotherapy Multi-specific antibody-like platforms.pdf
Next generation technologies for the optimal implementation of immunotherapy Q&A.mp4
Novel clinical and translational insights in melanoma Monitoring and refining melanoma patient care for immunotherapy.mp4
Novel clinical and translational insights in melanoma Monitoring and refining melanoma patient care for immunotherapy.pdf
Novel clinical and translational insights in melanoma Novel therapeutic immunotherapy modalities in cutaneous melanoma.mp4
Novel clinical and translational insights in melanoma Novel therapeutic immunotherapy modalities in cutaneous melanoma.pdf
Novel clinical and translational insights in melanoma Q&A.mp4
Novel clinical and translational insights in melanoma Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.pdf
Poster Display session 100P – Immunotherapy around the clock impact on stage IV melanoma.pdf
Poster Display session 101P – Safety and effectiveness of pembrolizumab.pdf
Poster Display session 102P – A Multicenter Retrospective Cohort Study.pdf
Poster Display session 103P – Phase IIIb study of durvalumab plus.pdf
Poster Display session 104P – Camrelizumab combined with chemotherapy.pdf
Poster Display session 105P – Neoadjuvant tislelizumab combined.pdf
Poster Display session 106P – Zanubrutinib in combination with tislelizumab.pdf
Poster Display session 107P – Outcomes of patients with metastatic non-small-cell lung cancer.pdf
Poster Display session 108P – Role of the prognostic nutritional index.pdf
Poster Display session 109P – Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety.pdf
Poster Display session 10P – Deep Learning-based prediction of patientOs.pdf
Poster Display session 110P – Fecal Microbiota Transplantation.pdf
Poster Display session 111P – Identification of Atezolizumab plus.pdf
Poster Display session 112P – Pseudoprogression predicts better prognosis.pdf
Poster Display session 113P – The prognostic and predictive roles of serum.pdf
Poster Display session 114P – Systemic Inflammatory Index as a prognostic.pdf
Poster Display session 115P – Reflectance Confocal Microscopy – An In Vivo.pdf
Poster Display session 116P – Clinical Significance of Serum-derived.pdf
Poster Display session 117P – Beta-Blockers in Lung Cancer Patients Receiving Immunotherapy.pdf
Poster Display session 118P – Immunosenescence and response to immunotherapy in elderly patients A possible.pdf
Poster Display session 119TiP – An observational study to assess the effectiveness.pdf
Poster Display session 11P – Association of VISTA expressing CD66b positive.pdf
Poster Display session 120TiP – Conversion of Response to Immune Checkpoint Inhibition by Fecal Microbiota.pdf
Poster Display session 121TiP – Prospective, single arm, phase II clinical trial of pembrolizumab combined.pdf
Poster Display session 123P – IMpower010 exploratory overall survival (OS).pdf
Poster Display session 124P – Phase II Study of Neoadjuvant Concurrent.pdf
Poster Display session 125P – A phase 2a study of the novel immunogenic.pdf
Poster Display session 126P – AdvanTIG-105 Phase 1b Dose-Expansion Study.pdf
Poster Display session 127P – Phase 1 study of fianlimab, a human.pdf
Poster Display session 128P – Neoadjuvant durvalumab plus chemotherapy.pdf
Poster Display session 129P – Tislelizumab Combined with Bevacizumab Plus.pdf
Poster Display session 12P – Multi-omics correlation with clinical outcome.pdf
Poster Display session 130P – COM701 Nivolumab – preliminary results of.pdf
Poster Display session 131P – First-line HDACi plus Tislelizumab combined.pdf
Poster Display session 132P – Randomized Phase 3 Study of Tislelizumab Plus.pdf
Poster Display session 133P – Efficacy of Nivolumab Immunotherapy in Non.pdf
Poster Display session 134P – Safety and efficacy of multi-target TKI.pdf
Poster Display session 135P – Camrelizumab plus chemotherapy as first-line.pdf
Poster Display session 136P – Tislelizumab (TIS) plus chemotherapy (chemo).pdf
Poster Display session 137P – Tislelizumab Combined with Chemotherapy as.pdf
Poster Display session 138P – Randomized Phase 3 Study of Tislelizumab Plus.pdf
Poster Display session 139P – The timing, dynamics, and co-occurrence of.pdf
Poster Display session 13P – Tumor infiltrating CD8 CD103 TIM-3-expressing.pdf
Poster Display session 140P – Patient-Reported Outcomes (PRO) Following.pdf
Poster Display session 141P – Efficacy and Safety of Tislelizumab Combined.pdf
Poster Display session 142P – CODAK real-world study Interim analysis of.pdf
Poster Display session 143P – Efficacy and safety of bronchial arterial.pdf
Poster Display session 144P – Toripalimab plus chemotherapy as neoadjuvant.pdf
Poster Display session 145P – Preliminary results of a phase II study of.pdf
Poster Display session 146P – Stereotactic body radiotherapy plus anlotinib.pdf
Poster Display session 148P – AdvanTIG-105 Phase 1b Dose-Expansion Study.pdf
Poster Display session 149P – A phase Ib II trial of surufatinib plus.pdf
Poster Display session 14P – Deep learning-based quantification of immune.pdf
Poster Display session 150P – Phase 1 study of fianlimab, a human.pdf
Poster Display session 151P – Clinical outcome and preliminary immune.pdf
Poster Display session 152P – A Phase I Study of HBM4003, an anti-CTLA-4.pdf
Poster Display session 153P – Neoadjuvant therapy with tislelizumab plus.pdf
Poster Display session 154P – Neoadjuvant chemotherapy plus tislelizumab.pdf
Poster Display session 155P – BNT113 + pembrolizumab as first-line.pdf
Poster Display session 156P – A Phase 1b 2 Study of Nanatinostat (Nstat) Plus.pdf
Poster Display session 158P – Triple blockade of the DNAM-axis with COM701.pdf
Poster Display session 159P – COM701 in combination with nivolumab.pdf
Poster Display session 15P – Prediction for pCR after Neoadjuvant.pdf
Poster Display session 160P – COLUMBIA-1 A Phase Ib II, Open-Label.pdf
Poster Display session 161P – A Phase 1b Study to Evaluate IK-007.pdf
Poster Display session 162P – Efficacy and safety of GEMOX.pdf
Poster Display session 163P – Neoadjuvant Chemoradiotherapy plus.pdf
Poster Display session 164P – TQB2450 plus anlotinib combined with paclitaxel.pdf
Poster Display session 165P – Efficacy and safety of tislelizumab.pdf
Poster Display session 166P – Combination of 5-fluorouracil (FU), interferon (IFN)-alpha2.pdf
Poster Display session 167P – TisCRT-LAPC A phase II clinical trial.pdf
Poster Display session 168P – Liver metastases (mets) and treatment effect.pdf
Poster Display session 169P – Immunomodulatory effects of RBS2418.pdf
Poster Display session 170P – EO2401 microbiome derived therapeutic vaccine.pdf
Poster Display session 171P – Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX.pdf
Poster Display session 172P – Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor.pdf
Poster Display session 173P – First-in-human study to evaluate the safety and clinical activity of FS222.pdf
Poster Display session 174P – First-in-human Study of NGM707, An ILT2 ILT4 Dual Antagonist Antibody.pdf
Poster Display session 175P – Safety and Preliminary Efficacy of GEN1042 (DuoBody-CD40x4-1BB).pdf
Poster Display session 176P – Phase 1 Study of INCB106385 Alone or in Combination with Immunotherapy.pdf
Poster Display session 177P – Targeting of immune regulatory proteins.pdf
Poster Display session 178P – Antibody engineering to evaluate binding, internalisation.pdf
Poster Display session 179P – Early Proof of Concept of Safety and Clinical.pdf
Poster Display session 17P – Using ex vivo organ culture technology to.pdf
Poster Display session 180P – Recalling pre-existing microbiota-specific T cells to target tumors.pdf
Poster Display session 181P – SELECT- A phase 2 randomized trial evaluating.pdf
Poster Display session 182P – Cancer vaccines based on whole-tumor-lysate.pdf
Poster Display session 183P – COMMANDER-001 Initial safety data from.pdf
Poster Display session 184P – A Phase I Study of the cancer-specific vaccine FMPV-1.pdf
Poster Display session 185P – Interim analysis of the EOGBM1-18 study.pdf
Poster Display session 186P – Synergistic antitumor effect of gemcitabine.pdf
Poster Display session 187P – Phase 1 2 study of the oral CCR4 antagonist.pdf
Poster Display session 188P – IPH5201 as Monotherapy or in Combination.pdf
Poster Display session 189P – IL-10 enhances macrophage phagocytosis.pdf
Poster Display session 18P – Systematic evaluation of published predictive.pdf
Poster Display session 190P – Combination of IPH5201, a blocking antibody.pdf
Poster Display session 191P – Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy.pdf
Poster Display session 192P – Safety and clinical activity of IOA-244.pdf
Poster Display session 193P – CLAUDIN-1 Targeting Antibodies in Solid Tumors.pdf
Poster Display session 194P – Thermal ablation followed by intratumoral injection.pdf
Poster Display session 195TiP – A First-In-Human, Phase 1 a b Dose.pdf
Poster Display session 196TiP – A Phase 1 study of REGN6569, a GITR monoclonal antibody (mAb).pdf
Poster Display session 197TiP – First-in-human (FIH) Phase 1 2 study.pdf
Poster Display session 198TiP – DEDALUS trial a single-arm, phase 2, multi-center.pdf
Poster Display session 199TiP – A first-in-human phase I study of IPH5301.pdf
Poster Display session 19P – Effects of CTLA-4 Single Nucleotide.pdf
Poster Display session 201P – Phase II study of taminadenant (A2AR antagonist).pdf
Poster Display session 202P – The therapeutic cancer vaccine PDC.pdf
Poster Display session 203P – Early remodeling of systemic antitumor T cell.pdf
Poster Display session 204P – Tumor immune microenvironment.pdf
Poster Display session 205P – Pre-existing tumor host immunity characterization.pdf
Poster Display session 206P – Characterization of the immune microenvironment of recurrent.pdf
Poster Display session 207P – Impact of Lymphatic Vessel Derived Oxysterol on anti-tumor immunity.pdf
Poster Display session 208P – Sex hormones impact the response to immunotherapy in obese male mice.pdf
Poster Display session 209P – Single-cell profiling of tumor-associated neutrophils in advanced non-small.pdf
Poster Display session 20P – Human virome epitope-level antiviral antibody.pdf
Poster Display session 210P – Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell.pdf
Poster Display session 211P – A new role for CXCL3 in shaping the metastatic tumor microenvironment.pdf
Poster Display session 212P – Augmenting Cancer Immunotherapy by Targeting the Fes Kinase.pdf
Poster Display session 213P – Type-1 diabetes restricts melanoma growth by reprogramming intra-tumoral.pdf
Poster Display session 214P – Location matters oral cancer cells at the tumor invasive border that express GARP.pdf
Poster Display session 215P – Proteogenomics to guide neoantigen discovery in non-small cell lung cancer.pdf
Poster Display session 216P – Relationship between regulatory T lymphocytes (Treg).pdf
Poster Display session 217P – Characterization of immune cells in the tumor microenvironment of advanced bladder cancer.pdf
Poster Display session 218P – A symbiotic relationship between persistent.pdf
Poster Display session 219P – Spatial sequencing of T cell repertoire in breast cancer.pdf
Poster Display session 21P – Peripheral pre-existing T-cell immunity as.pdf
Poster Display session 220P – HDAC1 inhibition sensitizes refractory tumor cells to anti-PD-1.pdf
Poster Display session 221P – The role of TNF-alpha in thymus dysfunction during Acute myeloid leukemia.pdf
Poster Display session 222P – Platinum-based chemotherapy attenuates the CD8 T cell proliferative response.pdf
Poster Display session 223P – Single-cell RNA-seq dissecting the stemness of tumor cells and the tumor.pdf
Poster Display session 224P – Immune characterization of de novo metastatic breast cancer.pdf
Poster Display session 225P – Ovarian cancer-cell glucocorticoid receptor activity modulates cytokine secretion.pdf
Poster Display session 226P – LncRNA DILC and PD-L1 Inhibitors.pdf
Poster Display session 227P – The elusive Luminal B breast tumor and the mysterious chemokines.pdf
Poster Display session 228P – Modelling T Cell-Vasculature interaction in a high-throughput microfluidic platform.pdf
Poster Display session 229P – Identify the impact of SARS-CoV-2 on Lung Cancer tumorigenesis.pdf
Poster Display session 22P – Mean platelet volume to lymphocyte ratio.pdf
Poster Display session 230P – A novel cross-platform concordance analysis using MultiOmyx and PhenoImager.pdf
Poster Display session 231P – Characterization of the tumor microenvironment in a cohort of KRAS.pdf
Poster Display session 232P – The efficacy of vasohibin 2 gene expression knockdown and biological relevance.pdf
Poster Display session 233P – Tumor characteristics of mixed response upon immune checkpoint inhibition (ICI).pdf
Poster Display session 234P – Oncolytic adenovirus-based therapeutics to reprogram the glioblastoma microenvironment.pdf
Poster Display session 235P – Multiplexed Imaging Reveals the Immunomodulatory cGAS as a Predictor.pdf
Poster Display session 236P – A novel microfluidic platform for understanding the role of PDAC stroma in immune response.pdf
Poster Display session 237P – Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients.pdf
Poster Display session 238P – Exploring blood immune cell dynamics.pdf
Poster Display session 239P – Survival outcomes predicted by irAEs.pdf
Poster Display session 23P – Enriching for response patient selection.pdf
Poster Display session 240P – AMU Using mRNA Embedding in Transformer Network.pdf
Poster Display session 241P – Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy.pdf
Poster Display session 242P – Educational needs of healthcare professionals using immune checkpoint inhibitors.pdf
Poster Display session 243P – Skin biopsies for pharmacodynamic studies of tebentafusp, a novel bispecific.pdf
Poster Display session 244P – DNA-PK inhibition sustains immune activation in SCLC.pdf
Poster Display session 24P – The predictive and prognostic role of single.pdf
Poster Display session 26P – Impact of SF3B1 mutation on response to immunotherapy.pdf
Poster Display session 27P – Gene ontology enrichment analysis of peripheral.pdf
Poster Display session 28P – Epithelial Mesenchymal transition confers.pdf
Poster Display session 29P – Circulating proteins associated with.pdf
Poster Display session 30P – Frequency of peripheral CD8+ T cells expressing.pdf
Poster Display session 31P – The IOpener study tyrosine kinase activity.pdf
Poster Display session 32P – Discovering markers that identify pro-metastatic immune cell subsets.pdf
Poster Display session 33P – Changes in serum cytokine CXCL12 level can.pdf
Poster Display session 34TiP – Prospective Analysis of INteStinal Microbiome.pdf
Poster Display session 39P – The expanded CD8+ tumor-infiltrating.pdf
Poster Display session 40P – Can we predict which TIL products will react.pdf
Poster Display session 41P – Single-Cell Signalling Analysis of Engineered.pdf
Poster Display session 42P – Tumor-reactive CD8+ T cells in ovarian and colon cancer in tumors and cell products.pdf
Poster Display session 43P – Development of a production process to.pdf
Poster Display session 44P – In situ CAR Therapy Using oRNA Lipid.pdf
Poster Display session 45P – The RevCAR T cell platform a switchable.pdf
Poster Display session 46P – Development of an allogeneic CAR-T targeting MUC1-C.pdf
Poster Display session 47P – Phase 1 Study to Assess the Safety and Efficacy.pdf
Poster Display session 48P – Phase II trial on vaccination with Autologous.pdf
Poster Display session 49P – Exploiting multi-omic integrated data from DC-vaccinated.pdf
Poster Display session 4P – FDG PET derived Metabolic Tumor Volume (MTV).pdf
Poster Display session 50P – Enhancing TIL and NK cells adoptive therapies.pdf
Poster Display session 51P – Immunological analysis of blood from patients.pdf
Poster Display session 52P – MUC1 targeted immunotherapy with an oncolytic adenovirus coding.pdf
Poster Display session 53P – Combining cancer vaccines based on arenavirus.pdf
Poster Display session 54P – Oncolytic virus combined PD-1 antibody.pdf
Poster Display session 55P – Mutations Localized at the Membrane Predict Immunotherapeutic Efficacy in Cancer Treatment.pdf
Poster Display session 5P – Tumor microenvironment cellular crosstalk.pdf
Poster Display session 63P – Activity and safety of first-line treatments for advanced melanoma.pdf
Poster Display session 64P – Safety and efficacy of immune checkpoint inhibitors.pdf
Poster Display session 65P – Atezolizumab plus bevacizumab versus.pdf
Poster Display session 66P – Real-world data of first-line chemo-immunotherapy.pdf
Poster Display session 67P – Real Word Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma.pdf
Poster Display session 69P – A Real-World Analysis of Treatment-Free survival for Advanced Melanoma.pdf
Poster Display session 6P – Response and survival according to the.pdf
Poster Display session 70P – A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal.pdf
Poster Display session 71P – Real-world Treatment Patterns and Clinical Outcomes for patients received Sintilimab.pdf
Poster Display session 72P – Treatments response in non-small cell lung.pdf
Poster Display session 73P – A randomized phase II study of neoadjuvant.pdf
Poster Display session 74P – The safety, tolerability, and preliminary.pdf
Poster Display session 75P – Effectiveness and safety data from IMreal Cohort 1.pdf
Poster Display session 76P – Safety profile of adjuvant pembrolizumab.pdf
Poster Display session 77P – A Study to Evaluate the Safety, Tolerability and.pdf
Poster Display session 78P – Clinical outcomes with atezolizumab plus.pdf
Poster Display session 79P – Efficacy and Safety of Zimberelimab (GLS-010).pdf
Poster Display session 7P – PrimeCUTR Identifying clinically relevant.pdf
Poster Display session 80P – Penpulimab (Anti-PD-1) combined with anlotinib.pdf
Poster Display session 81P – Is PD-1 inhibitor based treatment better than.pdf
Poster Display session 82P – Preliminary analysis of tislelizumab (TIS).pdf
Poster Display session 83P – The Immune-related adverse event (IRAE).pdf
Poster Display session 84P – Ambulatory management of ICI-induced.pdf
Poster Display session 85P – Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy.pdf
Poster Display session 86P – Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab.pdf
Poster Display session 87P – Infliximab use in patients with checkpoint inhibitor toxicities.pdf
Poster Display session 88P – Hepatic arterial infusion chemotherapy(HAIC).pdf
Poster Display session 89P – Durvalumab could be effective in combination.pdf
Poster Display session 8P – Phenotypic characterization of infused tumor-infiltrating lymphocytes.pdf
Poster Display session 90P – Long-term outcomes in melanoma patients.pdf
Poster Display session 91P – Association between weight variation.pdf
Poster Display session 92P – NEoadjuvant multimodality RX including.pdf
Poster Display session 93P – Cetuximab-based chemotherapy after.pdf
Poster Display session 94P – Does hyperprogressive disease predict poor survival.pdf
Poster Display session 95P – A phase II study of combination of H101.pdf
Poster Display session 96P – Long-term outcomes after initial disease progression with anti-PD-1 in melanoma.pdf
Poster Display session 97P – Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin.pdf
Poster Display session 98P – First-line atezolizumab durvalumab plus.pdf
Poster Display session 99P – Sintilimab plus nab-paclitaxel in platinum-refractory.pdf
Predictive factors for T cell therapy Q&A.mp4
Predictive factors for T cell therapy Radiotherapy and T cell infiltration into tumours.pdf
Predictive factors for T cell therapy T cells in clinical immunotherapy for gynaecological cancers.mp4
Predictive factors for T cell therapy T cells in clinical immunotherapy for gynaecological cancers.pdf
Predictive factors for T cell therapy The dynamics of T cell receptor signalling in cancer immunotherapy.mp4
Predictive factors for T cell therapy The dynamics of T cell receptor signalling in cancer immunotherapy.pdf
Proffered Paper session 1O – IMpower010 ctDNA status in patients (pts).mp4
Proffered Paper session 1O – IMpower010 ctDNA status in patients (pts).pdf
Proffered Paper session 56O – A randomized, controlled, multicenter phase II.mp4
Proffered Paper session 56O – A randomized, controlled, multicenter phase II.pdf
Proffered Paper session 57O – Randomized Double-Blind Phase II Trial (PERLA).mp4
Proffered Paper session 57O – Randomized Double-Blind Phase II Trial (PERLA).pdf
Proffered Paper session 58O – Real-world overall survival (OS) with durvalumab.mp4
Proffered Paper session 58O – Real-world overall survival (OS) with durvalumab.pdf
Proffered Paper session Invited Discussant 1.mp4
Proffered Paper session Invited Discussant 1.pdf
Proffered Paper session Invited Discussant 2.mp4
Proffered Paper session Invited Discussant 2.pdf
Proffered Paper session Invited Discussant 3.mp4
Proffered Paper session Invited Discussant 3.pdf
Proffered Paper session LBA4 – Preliminary safety and efficacy of adagrasib.mp4
Proffered Paper session LBA4 – Preliminary safety and efficacy of adagrasib.pdf
Proffered Paper session LBA5 – A phase 2 study of neoadjuvant SHR-1701.mp4
Proffered Paper session LBA5 – A phase 2 study of neoadjuvant SHR-1701.pdf
Session in collaboration with SITC Moving beyond just T cells in the TME Conclusions.mp4
Session in collaboration with SITC Moving beyond just T cells in the TME Panel discussion.mp4
Session in collaboration with SITC Moving beyond just T cells in the TME Welcome and introduction.mp4
Shared and neoantigen vaccines and T cells Lessons learned from dendritic cell vaccines.mp4
Shared and neoantigen vaccines and T cells Lessons learned from dendritic cell vaccines.pdf
Shared and neoantigen vaccines and T cells Neoantigen reactive T cells plays a critical role in immunotherapy.pdf
Shared and neoantigen vaccines and T cells Q&A.mp4
The future of CNS tumors Learning from failures and driven by biology Future perspectives on brain tumours’ treatment.mp4
The future of CNS tumors Learning from failures and driven by biology Future perspectives on brain tumours’ treatment.pdf
The future of CNS tumors Learning from failures and driven by biology Q&A.mp4
The future of CNS tumors Learning from failures and driven by biology Successes, pitfalls, and failures A clinical perspective.mp4
The future of CNS tumors Learning from failures and driven by biology Successes, pitfalls, and failures A clinical perspective.pdf
The future of CNS tumors Learning from failures and driven by biology The immune microenvironment of primary and metastatic brain tumours.mp4
The future of CNS tumors Learning from failures and driven by biology The immune microenvironment of primary and metastatic brain tumours.pdf
The future of CNS tumors Learning from failures and driven by biology The integrated genomic and epigenomic landscape of brain tumours.mp4
The future of CNS tumors Learning from failures and driven by biology The integrated genomic and epigenomic landscape of brain tumours.pdf
Thoracic tumours Beyond PD(L)1 in thoracic tumors Novel targets and combinations.mp4
Thoracic tumours Beyond PD(L)1 in thoracic tumors Novel targets and combinations.pdf
Thoracic tumours Building on CAR-T experience in mesothelioma.mp4
Thoracic tumours Building on CAR-T experience in mesothelioma.pdf
Thoracic tumours Immune dynamics during lung cancer development, from premalignant to invasive.mp4
Thoracic tumours Immune dynamics during lung cancer development, from premalignant to invasive.pdf
Thoracic tumours Optimal integration of immunotherapy in the (neo)adjuvant setting.mp4
Thoracic tumours Optimal integration of immunotherapy in the (neo)adjuvant setting.pdf
Thoracic tumours Q&A.mp4
Tumour and immunometabolism Microbiota and nutrition to module I-O efficacy.pdf
Tumour and immunometabolism Q&A.mp4
Tumour and immunometabolism Regulation of inflammation by metabolites and nutrients in the tumor niche.mp4
Tumour and immunometabolism Regulation of inflammation by metabolites and nutrients in the tumor niche.pdf
Tumour microenvironment Q&A.mp4
Tumour microenvironment The role of the tumour microenvironment in oncolytic virotherapy for myeloma.mp4
Tumour microenvironment The role of the tumour microenvironment in oncolytic virotherapy for myeloma.pdf
Tumour microenvironment Tumour-associated macrophages in breast cancer.pdf
Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Introduction to the 2022 Award keynote lecture.mp4
Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Introduction to the 2022 Award keynote lecture.pdf
Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Welcome.mp4
Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Welcome.pdf
YO Mentorship 2 Setting up first-in-human experimental trials in immuno-oncology.pdf

Reviews

There are no reviews yet.

Be the first to review “European Society for Medical Oncology Immuno-Oncology Congress 2022”

Your email address will not be published. Required fields are marked *